NOS3 and cancer: Few biomarkers predicting drug response are available in clinical practice for many cancer types [28, 29] and as far as we know this is the first study to demonstrate the role of eNOS polymorphisms in relation to clinical outcome in advanced HCC patients receiving sorafenib.